Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IOV 2001

Next Previous
X
Search
Drug Profile

IOV 2001

Alternative Names: Autologous PBL; IOV2001.

Latest Information Update: 02 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Iovance Biotherapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia

Most Recent Events

  • 04 Nov 2019 US FDA approves IND application for IOV 2001 in chronic lymphocytic leukemia, before November 2019
  • 04 Nov 2019 Iovance Biotherapeutics plans a phase I/II trial (IOV-CLL-01) for IOV 2001 in Chronic lymphocytic leukaemia before the end of 2019
  • 23 Oct 2019 Phase-I/II clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT04155710)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top